和黄医药2024年年报业绩点评:肿瘤产品综合收入超预期,在手现金充沛25年多项催化

西部证券
26 Mar

业绩概述:2024年商业化产品持续放量:2024年公司肿瘤产品市场销售额5.01亿美元(+134%)。分产品看①呋喹海外销售额2.906亿美元(2023年1,510万美元),美国市场迅速放量以及全球十多个国家上市,销售额达到2亿美元,触发来自武田2,000万美元的里程碑付款;②呋喹替尼国内销售额1.15亿美元(+7%),子宫内膜癌新适应症24年12月获批;③索凡替尼国内销售额4,900万美元(+...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10